Description
A Two-arm, Randomized, Non-comparative, Phase 2 Trial of AGEN2034 (Anti-PD-1) as a Monotherapy or Combination Therapy With AGEN1884 (Anti-CTLA4) or With Placebo in Women With Recurrent Cervical Cancer (Second Line) - RaPiDS
Location: CPMC (San Francisco)
Please contact: ClinicalResearch@sutterhealth.org about study Agenus GOG 3028
View study details on ClinicalTrials.gov
Principal Investigator
Co-Investigator(s)
Recruitment Status
Active, Not Recruiting
Start Date
February 26, 2020